Oral jak inhibitor baricitinib effective in jia

Access through your institution Buy or subscribe Baricitinib, an oral inhibitor of Janus kinase 1 (JAK1) and JAK2, is safe and effective in the treatment of patients with juvenile idiopathic

arthritis (JIA), according to the results of a new phase III, placebo-controlled, withdrawal trial published in _The Lancet_. A previous phase III trial of tofacitinib had highlighted the

efficacy of JAK inhibition in JIA. The latest JUVE-BASIS trial aimed to assess the safety and efficacy of baricitinib in 220 patients with various forms of JIA (polyarticular JIA, extended

oligoarticular JIA, enthesitis-related arthritis or juvenile psoriatic arthritis) who had had an inadequate response to conventional synthetic or biologic DMARD therapy. This is a preview of

subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value

online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more

Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS:

* Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES ORIGINAL ARTICLE * Ramanan, A. V. et al. Baricitinib in juvenile idiopathic

arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. _Lancet_ https://doi.org/10.1016/S0140-6736(23)00921-2 (2023)

Article  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews Rheumatology http://www.nature.com/nrrheum/ Jessica McHugh Authors * Jessica

McHugh View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Jessica McHugh. RIGHTS AND PERMISSIONS Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE McHugh, J. Oral JAK inhibitor baricitinib effective in JIA. _Nat Rev Rheumatol_ 19, 539 (2023). https://doi.org/10.1038/s41584-023-01019-y

Download citation * Published: 02 August 2023 * Issue Date: September 2023 * DOI: https://doi.org/10.1038/s41584-023-01019-y SHARE THIS ARTICLE Anyone you share the following link with will

be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative